AUTHOR=Krawiec Michał , Śliwka Joanna , Pawlak Szymon , Kapałka Michał , Hamerling Paulina , Grzywacz Weronika , Hawel Wiktoria , Skórska Gabriela , Piekutowska-Abramczuk Dorota , Hrapkowicz Tomasz 

TITLE=A novel TAFAZZIN gene variant c.525_533del causing Barth syndrome and leading to heart transplantation: a case report

JOURNAL=Frontiers in Pediatrics

VOLUME=Volume 13 - 2025

YEAR=2025

URL=https://www.frontiersin.org/journals/pediatrics/articles/10.3389/fped.2025.1634258

DOI=10.3389/fped.2025.1634258

ISSN=2296-2360

ABSTRACT=IntroductionBarth syndrome (BTHS) is an ultra-rare genetic disease caused by a mutation in the TAFAZZIN gene, located on the X chromosome. This gene codes for the protein tafazzin, which is involved in the metabolism of the mitochondrial phospholipid - cardiolipin. Symptoms of this genetic defect include dilated cardiomyopathy (DCM), skeletal myopathy, neutropenia, growth retardation, reduced cholesterol levels, increased serum lactic acid levels, and hypoglycemia in the neonatal period.Case descriptionA Caucasian boy with DCM and left ventricular non-compaction associated with BTHS, caused by a previously unreported variant in the TAFAZZIN gene: NM_000116.4:c.525_533del; NP_000107.1:p.(His176_Phe178del) at NC_000023.11:g.154419607_154419615del, in the exon 6. Due to the patient's heart failure, a mechanical circulatory support (MCS) system was required, followed by orthotopic heart transplantation (OHT). Because of the presence of neutropenia, standard immunosuppressive therapy had to be modified in the postoperative period.ConclusionsA previously unreported mutation is presented, leading to BTHS. This disease can have severe cardiovascular manifestations, requiring MCS and OHT.